[
    {
        "公司名稱": "生脈生物科技股份有限公司/LIFEMAXBIOTECHNOLOGY,INC.",
        "成立時間": "2014",
        "統一編號": "24747226",
        "公司狀態": "核准設立",
        "團隊人數": "未揭露",
        "實收資本額(元/新台幣)": "9,150,000",
        "負責人": "許中強(HSUChung-Chiang)",
        "主分類": "Biotechnology",
        "官方網站": "https://www.lifemaxlabs.com/home1380",
        "專利狀況": "公告專利總數︰0；發明專利︰0；新型專利︰0；設計專利︰0",
        "產品/服務簡介": "Therearemorethan7,000orphandiseasesinexistencetoday,andyetonlyabout5%ofthemhavetreatmentavailable.Werecognizethetremendousunmetmedicalneedsandarealopportunitytomakeameaningfuldifferenceinthelivesofthesepatientsandfamilies.Assuch,LifeMaxdedicatesitselftothedevelopmentoffirst-in-classorbest-in-classtherapeuticsfororphandiseases.Throughlicensingandcollaboration,wehavebuiltarobustandscience-drivenportfoliothataddressescriticalunmetmedicalneedsforthetreatmentoforphandiseases.Wecontinuetoexpandthepipelinewithafocusonmodalitiesthattargettheunderlyinggeneticcause.Withitsrobustpipelineandseasonedmanagementteam,LifeMaxiswellpositionedtogrowintoaleaderinthedevelopmentandcommercializationofnovelorphandrugs.",
        "公司簡介": "LifeMaxisaprivatelyheld,clinicalstagebiotechcompanyfocusedondevelopingfirst-in-classorbest-in-classtherapeuticsfororphandiseasesthathavefewornooptions.Ourleadprogram,LM-030,isreadytoenterintoapivotaltrialforthetreatmentofNethertonsyndrome.LifeMaxwasestablishedbyfourfounders,ledbyDr.LarryHsu,awell-knownentrepreneurandindustryveteran,withagoaltobuildacompanythatwouldbecomealeaderinthedevelopmentandcommercializationofmuchneededtherapeuticstoaddresscriticalunmetmedicalneeds.LifeMaxdistinguishesitselffromotherbiotechcompanieswithanexperiencedmanagementteamthathasaproventrackrecordofhavingsuccessfullybuiltafullyintegratedmulti-billiondollarNASDAQ-listedUSpharmaceuticalcompany.",
        "公司註冊地址": "臺北市大安區敦化南路2段97號2樓"
    }
]